Evaluation of the effect of the neurotoxin MPTP and the antiparkinsonian drug hemantane on the DNA integrity in the brain structures of C57BL/6 mice-Reference-Cited by-同舟云学术

Evaluation of the effect of the neurotoxin MPTP and the antiparkinsonian drug hemantane on the DNA integrity in the brain structures of C57BL/6 mice

Published:2022-02-22 Issue:4 Volume: Page:47-52
ISSN:2686-8830
Container-title:Pharmacokinetics and Pharmacodynamics
language:
Short-container-title:Fk&Fd

Author:

Anisina E. A.¹^ORCID,Zhanataev A. K.¹^ORCID,Nepoklonov A. V.¹,Kotelnikova S. O.¹^ORCID,Valdman E. A.¹^ORCID

Affiliation:

1. FSBI “Zakusov Institute of Pharmacology”

Abstract

Hemantane (N-adamant-2-yl-hexamethylenimine hydrochloride) is an antiparkinsonian drug with a multicomponent mechanism of action, including a modulating effect on the activity of dopamine and serotonergic mediator systems, a selective inhibitory effect on MAO-B, properties of a low-affinity non-competitive channel blocker of glutamate NMDA receptors, has moderate antiradical and anti-inflammatory activity. The aim of this study was to assess the effect of the neurotoxin MPTP, which is used for modeling of parkinsonian syndrome, and the hemantane on the DNA integrity in the striatum and frontal cortex of the brain of C57BL/6 mice by the DNA comet assay – gel electrophoresis of DNA single cells. Results. In the first experiment, hemantane was administered once a day for 5 days before the MPTP (20 mg/kg, i.p.), then together with MPTP once a day for 5 days. In the second experiment hemantane 10 mg/kg was injected preliminarily for 4 days and 40 minutes before MPTP 30 mg/kg. The obtained results confirm the absence of an effect on DNA of hemantane at a therapeutic dose of 10 mg / kg. In the experimental schemes used, we did not reveal the expected increase in the level of DNA damage under the influence of MPTP, and, accordingly, we were not able to assess the protective effect of hemantane.

Publisher

Publishing House OKI

Subject

Pharmacology (medical),Complementary and alternative medicine,Pharmaceutical Science

Reference22 articles.

1. Tissingh P, Bergmans J, Booij A et al. Drug-naive patients with Parkinson’s disease in Hoehn and Yahr stages I and II show a bilateral decrease in striatal dopamine transporters as revealed by [123I]beta- CIT SPECT. J Neurol. 1998;245(1):14–20. DOI: 10.1007/s004150050168.

2. Abaimov DA, Zimin IA, Kovalev GI. Subchronic effects of hemantane on the main subtypes of dopamine receptors in rat striatum ex vivo. Experimental and clinical pharmacology. 2008;71(1):18–21. (In Russ).

3. Abaimov D, Zimin I, Kudrin V, Kovalev G. Effects of antiparkinsonian drug hemantane on the level and metabolism of biogenic monoamines in brain structures of C57BL/6 mice. Experimental and clinical pharmacology. 2009;72(1):64–67. (In Russ).

4. Andiarzhanova EA, Valdman EA, Kudrin VS et al. Effect of a novel potential antiparkinsonian drug hemantane on the content of monoamines and its metabolites in the striatum of rats (microdialysis assay). Experimental and Clinical Pharmacology. 2001;64(6): 13–17. (In Russ).

5. Valdman EA, Voronina TA, Aksenova LN et al. Effect of a new antiparkinsonian drug hemantane on monoamine oxidase activity. Experimental and Clinical Pharmacology. 2003;5:3–5. (In Russ).